For Physicians

Healthcare providers (HCPs) face many challenges when trying to optimize care for their patients with HPV-driven cancers, including how to quickly and reliably identify any residual disease post-treatment, and easily monitor for recurrence.

Tumor-tissue–modified HPV (TTMV®) DNA is a unique blood-based biomarker that aids in detecting HPV-driven cancers, such as head and neck, anal, and cervical cancer.

NavDx® is the first and only clinically validated circulating TTMV HPV DNA blood test that can reveal the presence of HPV+ head and neck cancer and optimize care at any stage of the patient care continuum.¹⁻³ NavDx uses proprietary technology to quantify fragments of circulating TTMV HPV DNA that tumor cells shed into the blood.¹

This highly accurate blood test can be used to confirm HPV genotype and establish baseline circulating TTMV HPV DNA level pretreatment, assess treatment response, identify molecular residual disease post-treatment, and detect recurrence earlier than it would present clinically via PET or CT scan.

The easy-to-interpret, actionable test report helps inform clinical decisions, enabling physicians to intervene earlier, which may result in improved outcomes.¹

>95% sensitivity for recurrence detection, as validated in a 3-year prospective clinical study¹
>99% probability of being recurrence-free as long as TTMV HPV DNA remains undetectable after treatment¹
Detects recurrences earlier than the current standard-of-care surveillance schedule¹˒³
Reports are issued within 7 calendar days from sample receipt by the Naveris lab

NavDx enables physicians to optimize HPV-driven cancer care and reassure patients that their disease is being effectively monitored.¹

Optimize HPV+ cancer care with NavDx to:
CONFIRM the tumor HPV genotype²
ASSESS treatment response¹
IDENTIFY the presence of post-treatment molecular residual disease, and accurately¹
DETECT recurrence significantly earlier than it would present clinically ¹⁻³

References: 1. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. 2020;38(10):1050-1058. 2. Chera BS, Kumar S, Beaty BT, et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer Res. 2019;25(15):4682-4690. 3. Head and neck cancers. Version 3.2021. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) 2021;

If you would like to order NavDx for your patients please complete the form below, or email us at

Enter information or upload file